RTW Biotech Opportunities Ltd (LSE: RTWG), the London Stock Exchange-listed life sciences investment company, has announced an expansion of its Capital Allocation Plan on 9 November 2026, committing a further $42.8 million to a liquidity pool earmarked for NAV-accretive share buybacks. The company also formalised a new policy of allocating up to 20% of realised gains from merger and acquisition transactions to fund future capital returns. The move follows the near-completion of the original $45 million buyback commitment, with $42.3 million already returned to shareholders. Investors may be watching closely given the company's active portfolio M&A environment and the scale of the new commitment, equivalent to 4.9% of NAV as at 30 September 2026.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — London-listed life sciences investment fund managed by RTW Investments, LP
  • The company has expanded its Capital Allocation Plan, committing a further $42.8 million to a share buyback liquidity pool
  • $42.3 million of the original $45 million commitment has been returned; 7.2 million shares repurchased in the year to 5 November 2026; total liquidity pool now stands at $45.5 million (5.3% of NAV)
  • Investors should watch for further buyback activity and additional M&A exits within the portfolio

$42.3 Million Returned to Shareholders Since Prometheus Sale, Original $45 Million Target Near Complete

The company's original $45 million capital return programme, announced on 20 October 2025 following the sale of Prometheus, is now almost fully delivered. As at 5 November 2026, $42.3 million had been returned to shareholders through share buybacks, with 7.2 million shares repurchased in the year to that date. A residual $2.7 million remains outstanding from the original commitment. The announcement states that the total liquidity pool now stands at $45.5 million, representing 5.3% of NAV as at 30 September 2026, combining the remaining original allocation with the newly committed $42.8 million.

New Policy Formalises Up to 20% of Realised M&A Gains for Shareholder Capital Returns

The board has formalised a policy under which up to 20% of realised gains from M&A transactions may be allocated to a liquidity pool available for capital returns to shareholders, primarily through NAV-accretive share buybacks. The announcement states this more formulaic approach is intended to give shareholders greater clarity on future returns. The newly committed $42.8 million represents 20% of cumulative M&A uplifts since and including the Prometheus transaction, net of amounts already returned via buybacks to 5 November 2026, and is additional to the original $45 million programme previously announced.

Portfolio M&A Activity Includes Acquisitions by Novartis, Boston Scientific, GSK, Eli Lilly, Biogen and AbbVie

The announcement details significant M&A activity across the RTWG portfolio since October 2025. These include Novartis's $12 billion acquisition of Avidity at a 46% premium, Boston Scientific's $14.5 billion acquisition of Penumbra at a 19% premium, GSK's $2.2 billion acquisition of RAPT Therapeutics at a 65% premium, Eli Lilly's $6.3 billion acquisition of Centessa at a 38% premium, Biogen's $5.6 billion acquisition of Apellis at a 140% premium, and AbbVie's $10.9 billion acquisition of Apogee at a 49% premium. BioMarin also acquired private holding Alesta for $275 million upfront, representing an estimated 41% uplift on the company's carrying value.

Biotech M&A Volumes at Record Levels Provide Sector Tailwind for RTWG Portfolio

The announcement notes that biotech M&A rebounded sharply in 2025, with $126 billion of deals completed — more than double the 2024 total. The company states that $120 billion of transactions were announced in 2026 to 30 September 2026, and that it expects 2026 to be one of the best years on record for biotech M&A deal volumes. This sector backdrop underpins the capital return strategy, though the company notes that maintaining sufficient liquidity remains critical to protect and grow value in portfolio companies over time, representing a continuing balance between direct returns and reinvestment.